Recently, the U.S. Food and Drug Administration (FDA) granted accelerated approval* to the drug Rozlytrek (entrectinib, Genentech/Roche**) as a treatment for patients, 12 years or older, whose tumors have a specific genetic defect known as an “NTRK gene fusion.”*** This is now the second drug that the FDA has approved to treat patients with this […]
Read more |
On a family vacation in 2011, Mac tried to catch a seagull. Using his boogie board to shield his movements, he inched his way across the sand, closing on his target. With the determination and strong-will that defined him, Mac patiently stalked his target for 20 minutes, taking great care with each step as to […]
Read more |If you need additional information, have a specific request, or would like a comment from National Brain Tumor Society, please use the contacts below:
Michael Antonellis
Chief Marketing Officer
617.393.2841
mantonellis@braintumor.org
Tom Halkin
Senior Manager of Communications
617.393.2849
thalkin@braintumor.org
